Concepts (151)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Opioid-Related Disorders | 12 | 2025 | 293 | 5.310 |
Why?
|
| Analgesics, Opioid | 16 | 2025 | 470 | 4.940 |
Why?
|
| Buprenorphine | 8 | 2025 | 107 | 4.070 |
Why?
|
| Opiate Substitution Treatment | 6 | 2025 | 38 | 3.200 |
Why?
|
| Narcotic Antagonists | 8 | 2025 | 112 | 2.550 |
Why?
|
| Prescription Drug Monitoring Programs | 5 | 2025 | 7 | 2.510 |
Why?
|
| Drug Overdose | 4 | 2024 | 72 | 2.230 |
Why?
|
| Naloxone | 4 | 2024 | 47 | 1.680 |
Why?
|
| Drug Prescriptions | 8 | 2025 | 230 | 1.680 |
Why?
|
| Practice Patterns, Physicians' | 9 | 2025 | 775 | 1.630 |
Why?
|
| Prescription Drugs | 3 | 2025 | 52 | 1.620 |
Why?
|
| Benzodiazepines | 3 | 2024 | 110 | 1.600 |
Why?
|
| Chronic Pain | 2 | 2024 | 159 | 1.330 |
Why?
|
| Health Expenditures | 4 | 2025 | 134 | 1.320 |
Why?
|
| Students, Pharmacy | 4 | 2025 | 81 | 1.190 |
Why?
|
| Controlled Substances | 2 | 2025 | 11 | 1.060 |
Why?
|
| Cross-Sectional Studies | 13 | 2024 | 3834 | 1.000 |
Why?
|
| Pharmacists | 5 | 2023 | 103 | 0.980 |
Why?
|
| Health Services Accessibility | 4 | 2025 | 697 | 0.960 |
Why?
|
| Cytochrome P-450 CYP2D6 Inhibitors | 1 | 2025 | 4 | 0.950 |
Why?
|
| Oxycodone | 1 | 2025 | 15 | 0.950 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 366 | 0.920 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 378 | 0.910 |
Why?
|
| Prescriptions | 5 | 2023 | 44 | 0.880 |
Why?
|
| Focus Groups | 2 | 2024 | 228 | 0.850 |
Why?
|
| Methadone | 1 | 2024 | 126 | 0.850 |
Why?
|
| Motivation | 2 | 2023 | 336 | 0.800 |
Why?
|
| Hypnotics and Sedatives | 1 | 2024 | 133 | 0.780 |
Why?
|
| Antidepressive Agents | 2 | 2025 | 332 | 0.780 |
Why?
|
| Pharmacies | 1 | 2022 | 15 | 0.760 |
Why?
|
| Texas | 10 | 2025 | 3622 | 0.760 |
Why?
|
| Self Efficacy | 1 | 2023 | 205 | 0.720 |
Why?
|
| Fear | 1 | 2023 | 198 | 0.720 |
Why?
|
| Health Policy | 2 | 2020 | 227 | 0.700 |
Why?
|
| Perception | 2 | 2025 | 229 | 0.670 |
Why?
|
| Alcoholism | 1 | 2023 | 246 | 0.660 |
Why?
|
| Education, Pharmacy | 2 | 2023 | 61 | 0.660 |
Why?
|
| Social Desirability | 1 | 2020 | 18 | 0.660 |
Why?
|
| Preceptorship | 1 | 2020 | 28 | 0.650 |
Why?
|
| Humans | 42 | 2025 | 131679 | 0.610 |
Why?
|
| United States | 13 | 2025 | 11804 | 0.580 |
Why?
|
| Adult | 19 | 2025 | 31719 | 0.570 |
Why?
|
| Interrupted Time Series Analysis | 3 | 2025 | 26 | 0.560 |
Why?
|
| Vaccines | 1 | 2022 | 384 | 0.540 |
Why?
|
| Health Risk Behaviors | 1 | 2017 | 8 | 0.520 |
Why?
|
| Child Restraint Systems | 1 | 2017 | 6 | 0.520 |
Why?
|
| Community Pharmacy Services | 1 | 2017 | 10 | 0.520 |
Why?
|
| Sickness Impact Profile | 1 | 2017 | 40 | 0.510 |
Why?
|
| Pandemics | 3 | 2023 | 1164 | 0.510 |
Why?
|
| Physicians | 1 | 2023 | 634 | 0.510 |
Why?
|
| Hospitalization | 2 | 2025 | 1939 | 0.510 |
Why?
|
| Depression | 1 | 2025 | 1350 | 0.470 |
Why?
|
| Budgets | 1 | 2015 | 16 | 0.450 |
Why?
|
| Attitude of Health Personnel | 2 | 2018 | 714 | 0.430 |
Why?
|
| Middle Aged | 14 | 2025 | 28888 | 0.430 |
Why?
|
| Mothers | 1 | 2017 | 371 | 0.410 |
Why?
|
| Young Adult | 9 | 2025 | 10104 | 0.400 |
Why?
|
| Female | 21 | 2025 | 71185 | 0.390 |
Why?
|
| Melanoma | 3 | 2024 | 920 | 0.390 |
Why?
|
| Intention | 2 | 2022 | 100 | 0.360 |
Why?
|
| Qualitative Research | 3 | 2024 | 708 | 0.350 |
Why?
|
| Hypoglycemic Agents | 1 | 2015 | 475 | 0.330 |
Why?
|
| Male | 15 | 2025 | 65266 | 0.330 |
Why?
|
| Retrospective Studies | 10 | 2025 | 17667 | 0.330 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2022 | 904 | 0.320 |
Why?
|
| Insulin | 1 | 2015 | 1151 | 0.310 |
Why?
|
| Health Care Surveys | 2 | 2023 | 282 | 0.300 |
Why?
|
| Surveys and Questionnaires | 5 | 2025 | 4050 | 0.300 |
Why?
|
| Logistic Models | 2 | 2024 | 1831 | 0.300 |
Why?
|
| Cohort Studies | 4 | 2025 | 5123 | 0.270 |
Why?
|
| West Virginia | 2 | 2017 | 7 | 0.260 |
Why?
|
| Multiple Sclerosis | 2 | 2020 | 390 | 0.250 |
Why?
|
| Textbooks as Topic | 1 | 2025 | 8 | 0.240 |
Why?
|
| Paroxetine | 1 | 2025 | 24 | 0.230 |
Why?
|
| Fluoxetine | 1 | 2025 | 45 | 0.230 |
Why?
|
| Habits | 1 | 2025 | 28 | 0.230 |
Why?
|
| Breast Neoplasms | 3 | 2025 | 2648 | 0.230 |
Why?
|
| Prescription Drug Misuse | 1 | 2025 | 8 | 0.230 |
Why?
|
| Reading | 1 | 2025 | 78 | 0.220 |
Why?
|
| Proportional Hazards Models | 2 | 2025 | 1405 | 0.220 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2015 | 1413 | 0.210 |
Why?
|
| Continuity of Patient Care | 1 | 2025 | 143 | 0.210 |
Why?
|
| Reproducibility of Results | 2 | 2023 | 2989 | 0.200 |
Why?
|
| Webcasts as Topic | 1 | 2023 | 9 | 0.200 |
Why?
|
| Nonprescription Drugs | 1 | 2024 | 54 | 0.200 |
Why?
|
| Help-Seeking Behavior | 1 | 2023 | 2 | 0.200 |
Why?
|
| Curriculum | 2 | 2025 | 784 | 0.190 |
Why?
|
| Parents | 2 | 2022 | 1125 | 0.190 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 162 | 0.180 |
Why?
|
| Drug Therapy, Combination | 1 | 2025 | 1170 | 0.180 |
Why?
|
| Cost-Benefit Analysis | 2 | 2025 | 543 | 0.180 |
Why?
|
| Immunotherapy | 2 | 2024 | 765 | 0.180 |
Why?
|
| Drug Storage | 1 | 2021 | 18 | 0.180 |
Why?
|
| Aged | 6 | 2025 | 21260 | 0.170 |
Why?
|
| Pain Management | 2 | 2024 | 199 | 0.170 |
Why?
|
| Faculty, Pharmacy | 1 | 2020 | 10 | 0.170 |
Why?
|
| Cancer Pain | 1 | 2020 | 25 | 0.170 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 19 | 0.160 |
Why?
|
| Azithromycin | 1 | 2020 | 45 | 0.160 |
Why?
|
| Internet | 1 | 2023 | 422 | 0.160 |
Why?
|
| Self Report | 1 | 2023 | 563 | 0.160 |
Why?
|
| Rural Population | 2 | 2025 | 260 | 0.160 |
Why?
|
| Drug Utilization | 1 | 2020 | 164 | 0.150 |
Why?
|
| Comorbidity | 1 | 2024 | 1600 | 0.150 |
Why?
|
| Hydrocodone | 1 | 2018 | 36 | 0.140 |
Why?
|
| Cost of Illness | 1 | 2020 | 291 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2025 | 1356 | 0.140 |
Why?
|
| Geriatrics | 1 | 2018 | 75 | 0.140 |
Why?
|
| Time Factors | 2 | 2025 | 6279 | 0.140 |
Why?
|
| Education, Pharmacy, Continuing | 1 | 2017 | 1 | 0.130 |
Why?
|
| Automobiles | 1 | 2017 | 4 | 0.130 |
Why?
|
| Skin Neoplasms | 1 | 2024 | 904 | 0.130 |
Why?
|
| Vaccination | 1 | 2022 | 1040 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 287 | 0.130 |
Why?
|
| Income | 1 | 2017 | 135 | 0.120 |
Why?
|
| Cluster Analysis | 1 | 2017 | 418 | 0.120 |
Why?
|
| Educational Status | 1 | 2017 | 281 | 0.120 |
Why?
|
| Adolescent | 6 | 2024 | 20982 | 0.120 |
Why?
|
| Risk Assessment | 1 | 2023 | 3695 | 0.100 |
Why?
|
| Treatment Outcome | 3 | 2024 | 12984 | 0.100 |
Why?
|
| Neoplasms | 1 | 2024 | 2969 | 0.070 |
Why?
|
| Patient Discharge | 2 | 2023 | 506 | 0.060 |
Why?
|
| Child, Preschool | 1 | 2022 | 15057 | 0.060 |
Why?
|
| Education, Pharmacy, Graduate | 1 | 2025 | 10 | 0.060 |
Why?
|
| Child | 2 | 2024 | 26299 | 0.060 |
Why?
|
| Markov Chains | 1 | 2025 | 100 | 0.060 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2025 | 126 | 0.060 |
Why?
|
| Multimorbidity | 1 | 2024 | 25 | 0.050 |
Why?
|
| Insurance, Health | 1 | 2024 | 140 | 0.050 |
Why?
|
| Problem-Based Learning | 1 | 2023 | 82 | 0.050 |
Why?
|
| Thyroid Gland | 1 | 2023 | 99 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2024 | 302 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2024 | 400 | 0.040 |
Why?
|
| Anticonvulsants | 1 | 2024 | 391 | 0.040 |
Why?
|
| Educational Measurement | 1 | 2023 | 317 | 0.040 |
Why?
|
| Students | 1 | 2023 | 251 | 0.040 |
Why?
|
| Sex Factors | 1 | 2024 | 1346 | 0.040 |
Why?
|
| Mastectomy | 1 | 2020 | 75 | 0.040 |
Why?
|
| Models, Economic | 1 | 2020 | 57 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 502 | 0.040 |
Why?
|
| Drug Substitution | 1 | 2018 | 24 | 0.040 |
Why?
|
| Linear Models | 1 | 2020 | 695 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2020 | 285 | 0.030 |
Why?
|
| Risk Factors | 2 | 2024 | 10959 | 0.030 |
Why?
|
| Registries | 1 | 2024 | 1599 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 741 | 0.030 |
Why?
|
| Anxiety | 1 | 2023 | 1028 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1517 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 313 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 1234 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2020 | 810 | 0.020 |
Why?
|